Journal of Movement Disorders

Original Articles

Trends in Physiotherapy Interventions and Medical Costs for Parkinson’s Disease in South Korea, 2011–2020: Dong-Woo Ryu, Jinse Park, Myung Jun Lee, Dallah Yoo, Sang-Myung Cheon; Received December 22, 2023 Accepted March 18, 2024 Published online March 19, 2024; DOI: https://doi.org/10.14802/jmd.23269 [Accepted]

189 View
13 Download

Abstract PDF: Objective
Physiotherapy (PT), an effective strategy for managing Parkinson’s disease (PD), can influence healthcare utilization. We analyzed trends in healthcare utilization, PT interventions, and medical costs among patients with PD.
Methods
Using data from the Korean National Health Insurance Service from 2011 to 2020, we analyzed the number of patients with PD and their healthcare utilization and assessed the odds ratio (OR) for receiving regular PTs.
Results
Over 10 years, 169,613 patients with PD were present. The number of patients with PD increased annually from 49,417 in 2011 to 91,841 in 2020. Patients with PD receiving PT increased from 4,847 (9.81%) in 2011 to 13,163 (14.33%) in 2020, and PT prescriptions increased from 81,220 in 2011 to 377,651 in 2019. Medical costs per patient with PD have increased from 1,686 United States Dollars (USD) in 2011 to 3,201 USD in 2020. Medical expenses for each patient with PD receiving PT increased from 6,581 USD in 2011 to 13,476 USD in 2020. Moreover, Regular PTs were administered to 31,782 patients (18.74%) and conducted only through hospitalization. Those in their 50s with disabilities demonstrated a high OR for regular PTs, while those aged 80 years or older and residing outside Seoul had a low OR.
Conclusions
The PD burden increased in South Korea between 2011 and 2020, including an increase in healthcare utilization and medical costs. The significant rise in medical expenses can be associated with increased PD prevalence and PT interventions. Regular PT applications remain restricted and have barriers to access.

Parkinson’s Disease, Impulsive-Compulsive Behaviors, and Health-Related Quality of Life: Marie Grall-Bronnec, Audrey Verholleman, Caroline Victorri-Vigneau, Juliette Leboucher, Elsa Thiabaud, Jean-Benoit Hardouin, Benoit Schreck, Tiphaine Rouaud, Monica Roy, Pascal Derkinderen, Gaëlle Challet-Bouju; J Mov Disord. 2024;17(1):82-88. Published online November 6, 2023; DOI: https://doi.org/10.14802/jmd.23042

866 View
74 Download

Abstract PDF Supplementary Material: Objective
A large body of literature has examined the links between the use of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) and the development of “impulsive-compulsive behaviors (ICBs).” Little is known regarding the link between the development of ICBs and health-related quality of life (HRQOL). We aimed to explore the factors that are associated with poorer HRQOL, especially in relation to DRT-induced ICBs, in a sample of PD patients.
Methods
This PARKADD (PARK: PARKinson’s disease; ADD: behavioral ADDictions) study was a prospective case‒control study initially designed to assess the factors associated with ICBs in PD patients. A prospective clinical follow-up was added, aiming to capture the long-term evolution of HRQOL in relation to ICBs occurring or worsening after the beginning of PD. We focused on sociodemographic and PD characteristics and the history or presence of ICBs. HRQOL was measured using the Parkinson’s Disease Questionnaire-8. A multivariate linear regression was performed to identify factors related to poorer HRQOL.
Results
A total of 169 patients were eligible for the follow-up study. The presence of an ICB, a higher levodopa equivalent daily dose (LEDD) and a longer PD duration were significantly associated with poorer HRQOL, with an interaction between LEDD and PD duration.
Conclusion
The presence of an ICB was related to poorer HRQOL and should be considered a crucial factor for the management of PD patients. Several studies were recently published that provide guidelines for the management of these patients, with recommendations based on two key principles: prevention and specific treatment.

Review Articles

Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease: Young Cha, Tae-Yoon Park, Pierre Leblanc, Kwang-Soo Kim; J Mov Disord. 2023;16(1):22-41. Published online January 12, 2023; DOI: https://doi.org/10.14802/jmd.22141

6,101 View
463 Download
9 Web of Science
9 Crossref

Abstract PDF

Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting 1%–2% of the population over the age of 65. As the population ages, it is anticipated that the burden on society will significantly escalate. Although symptom reduction by currently available pharmacological and/or surgical treatments improves the quality of life of many PD patients, there are no treatments that can slow down, halt, or reverse disease progression. Because the loss of a specific cell type, midbrain dopamine neurons in the substantia nigra, is the main cause of motor dysfunction in PD, it is considered a promising target for cell replacement therapy. Indeed, numerous preclinical and clinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells remains fraught with controversy due to fundamental ethical, practical, and clinical limitations. Groundbreaking work on human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, coupled with extensive basic research in the stem cell field offers promising potential for hPSC-based cell replacement to become a realistic treatment regimen for PD once several major issues can be successfully addressed. In this review, we will discuss the prospects and challenges of hPSC-based cell therapy for PD.

Citations

Citations to this article as recorded by

RNA-based controllers for engineering gene and cell therapies
Kei Takahashi, Kate E Galloway
Current Opinion in Biotechnology.2024; 85: 103026. CrossRef
Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells
Min Seong Kim, Hyesoo Kim, Gabsang Lee
Advanced Healthcare Materials.2024;[Epub] CrossRef
A recent update on drugs and alternative approaches for parkinsonism
Sneha Kispotta, Debajyoti Das, Shakti Ketan Prusty
Neuropeptides.2024; 104: 102415. CrossRef
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Jessica Cohen, Annette Mathew, Kirk D. Dourvetakis, Estella Sanchez-Guerrero, Rajendra P. Pangeni, Narasimman Gurusamy, Kristina K. Aenlle, Geeta Ravindran, Assma Twahir, Dylan Isler, Sara Rukmini Sosa-Garcia, Axel Llizo, Alison C. Bested, Theoharis C. Th
Cells.2024; 13(6): 511. CrossRef
Continuous immunosuppression is required for suppressing immune responses to xenografts in non-human primate brains
Su Feng, Ting Zhang, Zhengxiao He, Wenchang Zhang, Yingying Chen, Chunmei Yue, Naihe Jing
Cell Regeneration.2024;[Epub] CrossRef
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets
Alhamdu Adamu, Shuo Li, Fankai Gao, Guofang Xue
Frontiers in Aging Neuroscience.2024;[Epub] CrossRef
Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
David J. Rademacher
Biomedicines.2023; 11(4): 1187. CrossRef
Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases
Amir Gholamzad, Hadis Sadeghi, Maryam Azizabadi Farahani, Ali Faraji, Mahya Rostami, Sajad Khonche, Shirin Kamrani, Mahsa Khatibi, Omid Moeini, Seyed Armit Hosseini, Mohammadmatin Nourikhani, Mehrdad Gholamzad
Neurology Letters.2023; 2(2): 55. CrossRef
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?
Z. Pirtošek, V. Leta, P. Jenner, M. Vérin
Journal of Neural Transmission.2023; 130(11): 1395. CrossRef

Multiple System Atrophy: Advances in Diagnosis and Therapy: Hirohisa Watanabe, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Mizuki Ito; J Mov Disord. 2023;16(1):13-21. Published online December 20, 2022; DOI: https://doi.org/10.14802/jmd.22082

3,597 View
410 Download
2 Web of Science
2 Crossref

Abstract PDF

This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

Citations

Citations to this article as recorded by

A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
Kazuya Kawabata, Florian Krismer, Beatrice Heim, Anna Hussl, Christoph Mueller, Christoph Scherfler, Elke R. Gizewski, Klaus Seppi, Werner Poewe
Movement Disorders Clinical Practice.2024; 11(4): 381. CrossRef
The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy
Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Arjun Ahluwalia, Andrew Awuah Wireko, Tomas Ferreira, Joecelyn Kirani Tan, Maximillian Wolfson, Shankhaneel Ghosh, Viktoriia Horbas, Vandana Garg, Asma Perveen, Marios Papadakis, Ghulam Md Ashraf, Ath
CNS Neuroscience & Therapeutics.2024;[Epub] CrossRef

Case Report

Effect of Chelation Therapy on a Korean Patient With Brain Manganese Deposition Resulting From a Compound Heterozygous Mutation in the SLC39A14 Gene: Jae-Hyeok Lee, Jin-Hong Shin; J Mov Disord. 2022;15(2):171-174. Published online March 22, 2022; DOI: https://doi.org/10.14802/jmd.21143

2,778 View
184 Download
7 Web of Science
6 Crossref

Abstract PDF

Mutations in the manganese transporter gene SLC39A14 lead to inherited disorders of manganese metabolism. Chelation therapy with edetate calcium disodium (CaNa2EDTA) is known to effectively reduce manganese deposition. We describe the first identified Korean case of SLC39A14-associated manganism and the treatment response to a 5-year chelation therapy. An 18-year-old female presented with childhood-onset dystonia. Magnetic resonance imaging showed T1 hyperintensity throughout the basal ganglia, brainstem, cerebellum, cerebral and cerebellar white matter, and pituitary gland. Blood manganese levels were elevated, and whole-exome sequencing revealed compound heterozygous mutations in SLC39A14. Treatment with intravenous CaNa₂EDTA led to a significant reduction in serum manganese levels and T1 hyperintensities. However, her dystonia improved insignificantly. Hence, early diagnosis of this genetic disorder is essential because it is potentially treatable. Even though our treatment did not significantly reverse the establish deficits, chelation therapy could have been more effective if it was started at an earlier stage of the disease.

Citations

Citations to this article as recorded by

Recent progress toward understanding the role of ZIP14 in regulating systemic manganese homeostasis
Shannon McCabe, Kirsten Limesand, Ningning Zhao
Computational and Structural Biotechnology Journal.2023; 21: 2332. CrossRef
Metal-ion transporter SLC39A8 is required for brain manganese uptake and accumulation
Qingli Liu, Supak Jenkitkasemwong, Tamanna Afrin Prami, Shannon Morgan McCabe, Ningning Zhao, Shintaro Hojyo, Toshiyuki Fukada, Mitchell D. Knutson
Journal of Biological Chemistry.2023; 299(8): 105078. CrossRef
Loss of slc39a14 causes simultaneous manganese hypersensitivity and deficiency in zebrafish
Karin Tuschl, Richard J. White, Chintan Trivedi, Leonardo E. Valdivia, Stephanie Niklaus, Isaac H. Bianco, Chris Dadswell, Ramón González-Méndez, Ian M. Sealy, Stephan C. F. Neuhauss, Corinne Houart, Jason Rihel, Stephen W. Wilson, Elisabeth M. Busch-Nent
Disease Models & Mechanisms.2022;[Epub] CrossRef
Hereditary Disorders of Manganese Metabolism: Pathophysiology of Childhood-Onset Dystonia-Parkinsonism in SLC39A14 Mutation Carriers and Genetic Animal Models
Alexander N. Rodichkin, Tomás R. Guilarte
International Journal of Molecular Sciences.2022; 23(21): 12833. CrossRef
Pathophysiological studies of aging Slc39a14 knockout mice to assess the progression of manganese-induced dystonia-parkinsonism
Alexander N. Rodichkin, Melissa K. Edler, Jennifer L. McGlothan, Tomás R. Guilarte
NeuroToxicology.2022; 93: 92. CrossRef
Mechanisms of manganese-induced neurotoxicity and the pursuit of neurotherapeutic strategies
Edward Pajarillo, Ivan Nyarko-Danquah, Alexis Digman, Harpreet Kaur Multani, Sanghoon Kim, Patric Gaspard, Michael Aschner, Eunsook Lee
Frontiers in Pharmacology.2022;[Epub] CrossRef

Review Articles

Manganese and Movement Disorders: A Review: Dinkar Kulshreshtha, Jacky Ganguly, Mandar Jog; J Mov Disord. 2021;14(2):93-102. Published online April 6, 2021; DOI: https://doi.org/10.14802/jmd.20123

10,265 View
512 Download
16 Web of Science
16 Crossref

Abstract PDF

Scientific and technological advances achieved with industrial expansion have led to an ever-increasing demand for heavy metals. This demand has, in turn, led to increased contamination of soil, water and air with these metals. Chronic exposure to metals may be detrimental not only to occupational workers but also to the nonoccupational population exposed to these metals. Manganese (Mn), a commonly used heavy metal, is an essential cofactor for many enzymatic processes that drive biological functions. However, it is also a potential source of neurotoxicity, particularly in the field of movement disorders. The typical manifestation of Mn overexposure is parkinsonism, which may be difficult to differentiate from the more common idiopathic Parkinson’s disease. In addition to environmental exposure to Mn, other potential etiologies causing hypermanganesemia include systemic health conditions, total parenteral nutrition and genetic mutations causing Mn dyshomeostasis. In this review, we critically analyze Mn and discuss its sources of exposure, pathophysiology and clinical manifestations. We have highlighted the global public health impact of Mn and emphasize that movement disorder specialists should record a detailed social and occupational history to ensure that a toxic etiology is not misdiagnosed as a neurodegenerative disease. In the absence of a definite therapeutic option, early diagnosis and timely institution of preventive measures are the keys to managing its toxic effects.

Citations

Citations to this article as recorded by

Investigation of Heavy Metal Analysis on Medicinal Plants Used for the Treatment of Skin Cancer by Traditional Practitioners in Pretoria
Oluwaseun Mary Oladeji, Boikanyo Genneyrolter Kopaopa, Liziwe Lizbeth Mugivhisa, Joshua Oluwole Olowoyo
Biological Trace Element Research.2024; 202(2): 778. CrossRef
The Regulation of ZIP8 by Dietary Manganese in Mice
Suetmui Yu, Ningning Zhao
International Journal of Molecular Sciences.2023; 24(6): 5962. CrossRef
Manganese Neurotoxicity as a Stroke Mimic: A Case Report
Mohiudeen Alikunju, Nafeesathu Misiriyyah , Shaikh Sayeed Iqbal, Maria Khan
Cureus.2023;[Epub] CrossRef
Associations of ambient manganese exposure with brain gray matter thickness and white matter hyperintensities
Shinyoung Woo, Young Noh, Sang-Baek Koh, Seung-Koo Lee, Jung il Lee, Ho Hyun Kim, Sun- Young Kim, Jaelim Cho, Changsoo Kim
Hypertension Research.2023; 46(8): 1870. CrossRef
Manganese overexposure induces Parkinson-like symptoms, altered lipid signature and oxidative stress in C57BL/6 J mouse
Muxue Lu, Ping Deng, Lingling Yang, Xue Wang, Xiang Mei, Chao Zhou, Mengyan Chen, Zhou Zhou, Huifeng Pi, Lichuan Wu, Zhengping Yu
Ecotoxicology and Environmental Safety.2023; 263: 115238. CrossRef
The Role of Oxidative Stress in Manganese Neurotoxicity: A Literature Review Focused on Contributions Made by Professor Michael Aschner
David C. Dorman
Biomolecules.2023; 13(8): 1176. CrossRef
Small noncoding RNA dysregulation is implicated in manganism in a rat model of methylcyclopentadienyl manganese tricarbonyl-induced unrepaired striatum damage
Qifeng Zhu, Fan Jiang, Yuanbo Song, Lili Lu, Fajian He, Shuqi Huang, Zhaoying Huang, Jing Yao, Ningning Lei, Jianmin Huang, Shijin Lu
The Journal of Toxicological Sciences.2023; 48(10): 535. CrossRef
Differentiating Wild and Apiary Honey by Elemental Profiling: a Case Study from Mangroves of Indian Sundarban
Tanushree Gaine, Praveen Tudu, Somdeep Ghosh, Shouvik Mahanty, Madhurima Bakshi, Nabanita Naskar, Souparna Chakrabarty, Subarna Bhattacharya, Swati Gupta Bhattacharya, Kashinath Bhattacharya, Punarbasu Chaudhuri
Biological Trace Element Research.2022; 200(10): 4550. CrossRef
Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review
Efthalia Angelopoulou, Yam Nath Paudel, Sokratis G. Papageorgiou, Christina Piperi
Brain Sciences.2022; 12(2): 175. CrossRef
Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects
Ľuboš Nižnanský, Žofia Nižnanská, Roman Kuruc, Andrea Szórádová, Ján Šikuta, Anežka Zummerová
Journal of Clinical Medicine.2022; 11(4): 1147. CrossRef
Can therapeutic plasma exchange be life-saving in life-threatening manganese intoxication?
Emel Uyar, Esra Gurkas, Aysel Unlusoy Aksu, Serhat Emeksiz, Cigdem Seher Kasapkara, Nadide Basak Gulleroglu, Ikbal Ok Bozkaya, Kader Karlı Oguz
Transfusion and Apheresis Science.2022; 61(4): 103417. CrossRef
Manganese‐induced parkinsonism responsive to intranasal insulin: A case report
Mehri Salari, Masoud Etemadifar, Leila Dargahi, Neda Valian, Malihe Rezaee
Clinical Case Reports.2022;[Epub] CrossRef
The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease
Adrianne F. Pike, Ildikò Szabò, Robert Veerhuis, Luigi Bubacco
npj Parkinson's Disease.2022;[Epub] CrossRef
Effect of Chelation Therapy on a Korean Patient With Brain Manganese Deposition Resulting From a Compound Heterozygous Mutation in the SLC39A14 Gene
Jae-Hyeok Lee, Jin-Hong Shin
Journal of Movement Disorders.2022; 15(2): 171. CrossRef
Manganese chloride (MnCl2) induced novel model of Parkinson’s disease in adult Zebrafish; Involvement of oxidative stress, neuroinflammation and apoptosis pathway
Abhishek.P.R. Nadig, Bader Huwaimel, Ahmed Alobaida, El-Sayed Khafagy, Hadil Faris Alotaibi, Afrasim Moin, Amr Selim Abu Lila, Suman, Sahyadri. M, K.L. Krishna
Biomedicine & Pharmacotherapy.2022; 155: 113697. CrossRef
Çalışma Yaşamında Manganez Maruz Kalımının Sağlık Etkileri ve Parkinsonizm
Zehra GÖK METİN, Abdulsamet SANDAL, Ali Naci YILDIZ
Karaelmas İş Sağlığı ve Güvenliği Dergisi.2021; 5(2): 147. CrossRef

Update on Current Technologies for Deep Brain Stimulation in Parkinson’s Disease: Michelle Paff, Aaron Loh, Can Sarica, Andres M. Lozano, Alfonso Fasano; J Mov Disord. 2020;13(3):185-198. Published online August 31, 2020; DOI: https://doi.org/10.14802/jmd.20052

18,623 View
739 Download
51 Web of Science
52 Crossref

Abstract PDF

Deep brain stimulation (DBS) is becoming increasingly central in the treatment of patients with Parkinson’s disease and other movement disorders. Recent developments in DBS lead and implantable pulse generator design provide increased flexibility for programming, potentially improving the therapeutic benefit of stimulation. Directional DBS leads may increase the therapeutic window of stimulation by providing a means of avoiding current spread to structures that might give rise to stimulation-related side effects. Similarly, control of current to individual contacts on a DBS lead allows for shaping of the electric field produced between multiple active contacts. The following review aims to describe the recent developments in DBS system technology and the features of each commercially available DBS system. The advantages of each system are reviewed, and general considerations for choosing the most appropriate system are discussed.

Citations

Citations to this article as recorded by

Current DBS programming
Yıldız Değirmenci
Deep Brain Stimulation.2024; 4: 29. CrossRef
Technological developments in electric-based DBS
Mehmet Tonge
Deep Brain Stimulation.2024; 4: 36. CrossRef
Movement disorder Deep brain stimulation Hybridization: Patient and caregiver outcomes
Nathan Esplin, Dorian Kusyk, Seung W Jeong, Shahed Elhamdani, Khaled Abdel Aziz, Amanda Webb, Cindy Angle, Donald Whiting, Nestor D. Tomycz
Clinical Parkinsonism & Related Disorders.2024; 10: 100234. CrossRef
Deep brain stimulation of the subthalamic nucleus in Parkinson disease 2013–2023: where are we a further 10 years on?
Andrew Brian O’Keeffe, Anca Merla, Keyoumars Ashkan
British Journal of Neurosurgery.2024; : 1. CrossRef
Preventing Sudden Cessation of Implantable Pulse Generators in Deep Brain Stimulation: A Systematic Review and Protocol Proposal
Spencer J. Oslin, Helen H. Shi, Andrew K. Conner
Stereotactic and Functional Neurosurgery.2024; 102(2): 127. CrossRef
Janus microparticles-based targeted and spatially-controlled piezoelectric neural stimulation via low-intensity focused ultrasound
Mertcan Han, Erdost Yildiz, Ugur Bozuyuk, Asli Aydin, Yan Yu, Aarushi Bhargava, Selcan Karaz, Metin Sitti
Nature Communications.2024;[Epub] CrossRef
Spinal Cord Stimulation for Parkinson’s Disease: A Systematic Review and Meta-Analysis of Pain and Motor Outcomes
Can Sarica, Ajmal Zemmar, Omid Yousefi, Andrew C. Yang, Ayse Uzuner, Zhiyuan Sheng, Brendan Santyr, Nardin Samuel, Michael Colditz, Artur Vetkas, Jürgen Germann, Cletus Cheyuo, Mohammadmahdi Sabahi, Raja Niranjan Jani, Ghazaleh Darmani, Kazuaki Yamamoto,
Stereotactic and Functional Neurosurgery.2023; 101(4): 244. CrossRef
Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up
Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Nayoung Kim, Mi-Sun Kim, Sang Ryong Jeon, Sun Ju Chung
Journal of the Neurological Sciences.2023; 444: 120484. CrossRef
Implementing automation in deep brain stimulation: has the time come?
Marco Bonizzato, Alfonso Fasano
The Lancet Digital Health.2023; 5(2): e52. CrossRef
Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation
Joshua K. Wong, Helen S. Mayberg, Doris D. Wang, R. Mark Richardson, Casey H. Halpern, Lothar Krinke, Mattia Arlotti, Lorenzo Rossi, Alberto Priori, Sara Marceglia, Ro’ee Gilron, James F. Cavanagh, Jack W. Judy, Svjetlana Miocinovic, Annaelle D. Devergnas
Frontiers in Human Neuroscience.2023;[Epub] CrossRef
Deep brain stimulation: new programming algorithms and teleprogramming
Renato Puppi Munhoz, Ghadh Albuainain
Expert Review of Neurotherapeutics.2023; 23(5): 467. CrossRef
Impact of modeled field of view in electroconvulsive therapy current flow simulations
Alexander Guillen, Christopher C. Abbott, Zhi-De Deng, Yu Huang, Paula Pascoal-Faria, Dennis Q. Truong, Abhishek Datta
Frontiers in Psychiatry.2023;[Epub] CrossRef
Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
Manon Auffret, Daniel Weiss, Fabrizio Stocchi, Marc Vérin, Wolfgang H. Jost
Journal of Neural Transmission.2023; 130(11): 1411. CrossRef
Multifunctional Fiber‐Based Optoacoustic Emitter as a Bidirectional Brain Interface
Nan Zheng, Ying Jiang, Shan Jiang, Jongwoon Kim, Guo Chen, Yueming Li, Ji‐Xin Cheng, Xiaoting Jia, Chen Yang
Advanced Healthcare Materials.2023;[Epub] CrossRef
Neurological Insights into Sleep Disorders in Parkinson’s Disease
Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Mariappan, Subramanian Rashmi, Thiwanya Choeisoongnern, Phakkharawat Sittiprapaporn, Chaiyavat Chaiyasut
Brain Sciences.2023; 13(8): 1202. CrossRef
Investigation of a Deep Brain Stimulator (DBS) System
Jennifer Whitestone, Anmar Salih, Tarun Goswami
Bioengineering.2023; 10(10): 1160. CrossRef
Thirty Years of Global Deep Brain Stimulation: “Plus ça change, plus c’est la même chose”?
Marwan Hariz, Laura Cif, Patric Blomstedt
Stereotactic and Functional Neurosurgery.2023; 101(6): 395. CrossRef
The Safety to Switch from Constant Voltage to Constant Current with a Mixed Internal Pulse Generator in Deep Brain Stimulation
Gülşah Öztürk, Kemal Paksoy
Annals of Indian Academy of Neurology.2023; 26(4): 507. CrossRef
Advances in Deep Brain Stimulation: From Mechanisms to Applications
Stephanie S. Sandoval-Pistorius, Mallory L. Hacker, Allison C. Waters, Jing Wang, Nicole R. Provenza, Coralie de Hemptinne, Kara A. Johnson, Melanie A. Morrison, Stephanie Cernera
The Journal of Neuroscience.2023; 43(45): 7575. CrossRef
Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances
Thomas J. Foutz, Michael Wong
Biomedical Journal.2022; 45(1): 27. CrossRef
Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology
Raj Kumar, Keshaw Ram Aadil, Kunal Mondal, Yogendra Kumar Mishra, David Oupicky, Seeram Ramakrishna, Ajeet Kaushik
Critical Reviews in Biotechnology.2022; 42(8): 1180. CrossRef
Sleep and circadian rhythms in Parkinson’s disease and preclinical models
Jeremy Hunt, Elizabeth J. Coulson, Rajendram Rajnarayanan, Henrik Oster, Aleksandar Videnovic, Oliver Rawashdeh
Molecular Neurodegeneration.2022;[Epub] CrossRef
Jose Delgado: A controversial trailblazer in neuromodulation
Nicholas D. Lorusso, Uma R. Mohan, Joshua Jacobs
Artificial Organs.2022; 46(4): 531. CrossRef
Local and distant cortical responses to single pulse intracranial stimulation in the human brain are differentially modulated by specific stimulation parameters
Angelique C. Paulk, Rina Zelmann, Britni Crocker, Alik S. Widge, Darin D. Dougherty, Emad N. Eskandar, Daniel S. Weisholtz, R. Mark Richardson, G. Rees Cosgrove, Ziv M. Williams, Sydney S. Cash
Brain Stimulation.2022;[Epub] CrossRef
Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury
Joshua K. Wong, Günther Deuschl, Robin Wolke, Hagai Bergman, Muthuraman Muthuraman, Sergiu Groppa, Sameer A. Sheth, Helen M. Bronte-Stewart, Kevin B. Wilkins, Matthew N. Petrucci, Emilia Lambert, Yasmine Kehnemouyi, Philip A. Starr, Simon Little, Juan Ans
Frontiers in Human Neuroscience.2022;[Epub] CrossRef
Past, Present, and Future of Deep Brain Stimulation: Hardware, Software, Imaging, Physiology and Novel Approaches
Jessica Frey, Jackson Cagle, Kara A. Johnson, Joshua K. Wong, Justin D. Hilliard, Christopher R. Butson, Michael S. Okun, Coralie de Hemptinne
Frontiers in Neurology.2022;[Epub] CrossRef
Parkinson’s Disease Management via Wearable Sensors: A Systematic Review
Huma Mughal, Abdul Rehman Javed, Muhammad Rizwan, Ahmad S. Almadhor, Natalia Kryvinska
IEEE Access.2022; 10: 35219. CrossRef
Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic
Disep I. Ojukwu, Allan R. Wang, Traci S. Hornbeck, Erika A. Lim, Jennifer Sharrard, Rohit Dhall, Vivek P. Buch, Casey H. Halpern
Movement Disorders.2022; 37(6): 1321. CrossRef
Developments in Deep Brain Stimulators for Successful Aging Towards Smart Devices—An Overview
Angelito A. Silverio, Lean Angelo A. Silverio
Frontiers in Aging.2022;[Epub] CrossRef
Single-interface bioelectronic medicines—concept, clinical applications and preclinical data
Cristian Sevcencu
Journal of Neural Engineering.2022; 19(3): 031001. CrossRef
Current Steering Using Multiple Independent Current Control Deep Brain Stimulation Technology Results in Distinct Neurophysiological Responses in Parkinson’s Disease Patients
Jana Peeters, Alexandra Boogers, Tine Van Bogaert, Robin Gransier, Jan Wouters, Bart Nuttin, Myles Mc Laughlin
Frontiers in Human Neuroscience.2022;[Epub] CrossRef
Managing Intractable Symptoms of Parkinson's Disease: A Nonsurgical Approach Employing Infralow Frequency Neuromodulation
Stella B. Legarda, P. Andreas Michas-Martin, Dana McDermott
Frontiers in Human Neuroscience.2022;[Epub] CrossRef
Directional Deep Brain Stimulation in the Treatment of Parkinson's Disease
Akash Mishra, Ritesh A Ramdhani
Neurology.2022; 18(1): 64. CrossRef
Approach to the Treatment of Pediatric Dystonia
Carolina Gorodetsky, Alfonso Fasano
Dystonia.2022;[Epub] CrossRef
CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics
Tirthankar Sen, Rajkumar P. Thummer
Neurotoxicity Research.2022; 40(5): 1597. CrossRef
Encoding type, medication, and deep brain stimulation differentially affect memory-guided sequential reaching movements in Parkinson's disease
Fabian J. David, Yessenia M. Rivera, Tara K. Entezar, Rishabh Arora, Quentin H. Drane, Miranda J. Munoz, Joshua M. Rosenow, Sepehr B. Sani, Gian D. Pal, Leonard Verhagen-Metman, Daniel M. Corcos
Frontiers in Neurology.2022;[Epub] CrossRef
Remote programming for subthalamic deep brain stimulation in Parkinson's disease
Si Chen, Shu-jun Xu, Wei-guo Li, Teng Chen, Chao Li, Shuo Xu, Ning Yang, Yi-ming Liu
Frontiers in Neurology.2022;[Epub] CrossRef
Longevity of Deep Brain Stimulation Batteries; a Global Survey of Neurosurgeons and Neurologists
Marwan Hariz, Gun‐Marie Hariz, Patric Blomstedt
Movement Disorders.2021; 36(5): 1273. CrossRef
Basic Tips: How Do I Start Programming Deep Brain Stimulation in Parkinson Disease Patients?
Carolina Gorodetsky, Alfonso Fasano
Movement Disorders Clinical Practice.2021; 8(4): 639. CrossRef
Deep brain stimulation: Challenges at the tissue‐electrode interface and current solutions
Emily Kolaya, Bonnie L. Firestein
Biotechnology Progress.2021;[Epub] CrossRef
An Update on Medical and Surgical Treatments of Parkinson’s Disease
Dipali Nemade, Thyagarajan Subramanian, Vikram Shivkumar
Aging and disease.2021; 12(4): 1021. CrossRef
Experimental Characterization of Ferroelectric Capacitor Circuits for the Realization of Simply Designed Electroceuticals
Yves Olsommer, Frank R. Ihmig
Electronic Materials.2021; 2(3): 299. CrossRef
Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial
Derrick Soh, Ricardo Maciel, Musleh Algarni, Karlo Lizarraga, Aaron Loh, Jürgen Germann, Gavin Elias, Alexandre Boutet, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
Parkinsonism & Related Disorders.2021; 89: 93. CrossRef
Telemedicine and Deep brain stimulation - Current practices and recommendations
Vibhash D. Sharma, Delaram Safarpour, Shyamal H. Mehta, Nora Vanegas-Arroyave, Daniel Weiss, Jeffrey W. Cooney, Zoltan Mari, Alfonso Fasano
Parkinsonism & Related Disorders.2021; 89: 199. CrossRef
Subspace-based predictive control of Parkinson’s disease: A model-based study
Mahboubeh Ahmadipour, Mojtaba Barkhordari-Yazdi, Saeid R. Seydnejad
Neural Networks.2021; 142: 680. CrossRef
Advances in Triboelectric Nanogenerators for Self‐Powered Regenerative Medicine
Samira Parandeh, Niloofar Etemadi, Mahshid Kharaziha, Guorui Chen, Ardo Nashalian, Xiao Xiao, Jun Chen
Advanced Functional Materials.2021;[Epub] CrossRef
Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity
Can Sarica, Christian Iorio-Morin, David H. Aguirre-Padilla, Ahmed Najjar, Michelle Paff, Anton Fomenko, Kazuaki Yamamoto, Ajmal Zemmar, Nir Lipsman, George M. Ibrahim, Clement Hamani, Mojgan Hodaie, Andres M. Lozano, Renato P. Munhoz, Alfonso Fasano, Sun
Frontiers in Human Neuroscience.2021;[Epub] CrossRef
Microstimulation Is a Promising Approach in Achieving Better Lead Placement in Subthalamic Nucleus Deep Brain Stimulation Surgery
Lin Shi, Shiying Fan, Tianshuo Yuan, Huaying Fang, Jie Zheng, Zunyu Xiao, Yu Diao, Guanyu Zhu, Quan Zhang, Huanguang Liu, Hua Zhang, Fangang Meng, Jianguo Zhang, Anchao Yang
Frontiers in Neurology.2021;[Epub] CrossRef
Revisiting brain stimulation in Parkinson’s disease
Carola A. Haas
Science.2021; 374(6564): 153. CrossRef
A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinson’s Disease
Mattia Arlotti, Matteo Colombo, Andrea Bonfanti, Tomasz Mandat, Michele Maria Lanotte, Elena Pirola, Linda Borellini, Paolo Rampini, Roberto Eleopra, Sara Rinaldo, Luigi Romito, Marcus L. F. Janssen, Alberto Priori, Sara Marceglia
Frontiers in Neuroscience.2021;[Epub] CrossRef
Update on Parkinson's Disease Therapy
Rebecca M Gilbert
Neurology.2021; 17(2): 92. CrossRef
Deep Brain Stimulation for Parkinson's Disease: Currents Status and Emerging Concepts
PareshK Doshi, Deepak Das
Neurology India.2020; 68(8): 179. CrossRef

Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies: Junghwan Shin, Han-Joon Kim, Beomseok Jeon; J Mov Disord. 2020;13(1):11-19. Published online December 19, 2019; DOI: https://doi.org/10.14802/jmd.19057

10,280 View
457 Download
19 Web of Science
19 Crossref

Abstract PDF

α-Synuclein and tau deposition in the central nervous system is responsible for various parkinsonian syndromes, including Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. Emerging evidence has suggested that pathologic α-synuclein and tau are transmitted from cell to cell and further accelerate the aggregation of pathologic proteins in neighboring cells. Furthermore, extracellular pathologic proteins have also been reported to provoke inflammatory responses that lead to neurodegeneration. Therefore, immunotherapies targeting extracellular α-synuclein and tau have been proposed as potential disease-modifying strategies. In this review, we summarize completed phase I trials and ongoing phase II trials of immunotherapies against α-synuclein and tau and further discuss concerns and hurdles to overcome in the future.

Citations

Citations to this article as recorded by

Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration
Wen Li, Jia-Yi Li
Translational Neurodegeneration.2024;[Epub] CrossRef
Modeling the dynamics of innate and adaptive immune response to Parkinson's disease with immunotherapy
Salma M. Al-Tuwairqi, Asma A. Badrah
AIMS Mathematics.2023; 8(1): 1800. CrossRef
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy
Winston T. Chu, Jesse Hall, Anjela Gurrala, Alexander Becsey, Shreya Raman, Michael S. Okun, Catherine T. Flores, Benoit I. Giasson, David E. Vaillancourt, Vinata Vedam-Mai
ACS Chemical Neuroscience.2023; 14(2): 235. CrossRef
Direct digital sensing of protein biomarkers in solution
Georg Krainer, Kadi L. Saar, William E. Arter, Timothy J. Welsh, Magdalena A. Czekalska, Raphaël P. B. Jacquat, Quentin Peter, Walther C. Traberg, Arvind Pujari, Akhila K. Jayaram, Pavankumar Challa, Christopher G. Taylor, Lize-Mari van der Linden, Titus
Nature Communications.2023;[Epub] CrossRef
Inflammation in multiple system atrophy
Marta Leńska-Mieciek, Natalia Madetko-Alster, Piotr Alster, Leszek Królicki, Urszula Fiszer, Dariusz Koziorowski
Frontiers in Immunology.2023;[Epub] CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
Acta Neuropathologica.2022; 143(1): 55. CrossRef
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan,
npj Vaccines.2022;[Epub] CrossRef
Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
Thuy Thi Lai, Yun Joong Kim, Hyeo-il Ma, Young Eun Kim
Journal of Movement Disorders.2022; 15(1): 1. CrossRef
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies
Dhanya Vijayakumar, Joseph Jankovic
CNS Drugs.2022; 36(4): 327. CrossRef
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
Urmi Sengupta, Rakez Kayed
Progress in Neurobiology.2022; 214: 102270. CrossRef
Modeling the dynamics of innate immune response to Parkinson disease with therapeutic approach
Asma Badrah, Salma Al-Tuwairqi
Physical Biology.2022; 19(5): 056004. CrossRef
Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer's disease
Le Zhao, Dan Li, Xiaofen Qi, Kaifang Guan, Haoran Chen, Rongchun Wang, Ying Ma
Food & Function.2022; 13(21): 10851. CrossRef
Harnessing the immune system for the treatment of Parkinson’s disease
Vinata Vedam-Mai
Brain Research.2021; 1758: 147308. CrossRef
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
Katja Badanjak, Sonja Fixemer, Semra Smajić, Alexander Skupin, Anne Grünewald
International Journal of Molecular Sciences.2021; 22(9): 4676. CrossRef
Viral alpha-synuclein knockdown prevents spreading synucleinopathy
Sindhu Menon, Rikke H Kofoed, Fadl Nabbouh, Kristiana Xhima, Yasmeen Al-Fahoum, Tammy Langman, Howard T J Mount, Lamya S Shihabuddin, S Pablo Sardi, Paul E Fraser, Joel C Watts, Isabelle Aubert, Anurag Tandon
Brain Communications.2021;[Epub] CrossRef
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Somin Kwon, Michiyo Iba, Changyoun Kim, Eliezer Masliah
Neurotherapeutics.2020; 17(3): 935. CrossRef
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Kyu-Young Sim, Kyeong Chan Im, Sung-Gyoo Park
International Journal of Molecular Sciences.2020; 21(15): 5295. CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
Alzheimer's Research & Therapy.2020;[Epub] CrossRef
New Insights Into Drug Discovery Targeting Tau Protein
Yoshiyuki Soeda, Akihiko Takashima
Frontiers in Molecular Neuroscience.2020;[Epub] CrossRef

Original Articles

Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia: Mark M. Lin, Robert Laureno; J Mov Disord. 2019;12(1):37-42. Published online January 30, 2019; DOI: https://doi.org/10.14802/jmd.18046

9,208 View
279 Download
9 Web of Science
8 Crossref

Abstract PDF

Objective
To evaluate whether less pulsatile levodopa therapy (LPT) can reduce the development of levodopa-induced dyskinesia (LID).
Methods
This is a retrospective cohort study of patients with Parkinson’s disease at the movement disorders clinic of Medstar Washington Hospital Center. The study was not blinded or randomized. Patients were seen between August 2002 and August 2018. During these years, we treated patients with less pulsatile (6 doses daily) levodopa treatment to reduce LID. Occurrence of LID was recorded.
Results
Ninety-five patients with Parkinson’s disease taking levodopa were divided into two groups: 1) patients who were initially managed on LPT or who switched from traditional therapy (TT) (n = 61) (mean disease duration: 7.7 ± 4.8 years, mean levodopa duration: 5.6 ± 4.5 years and mean observation time: 4.3 ± 3.4 years), and 2) patients on TT throughout the observation period or until they developed dyskinesia (n = 34) (mean disease duration: 8.3 ± 3.8 years, mean levodopa duration: 6.2 ± 4.2 years and mean observation time: 4.1 ± 3.4 years). Three of the 61 LPT patients developed dyskinesia during the observation period. One of the patients developed dyskinesia after being switched to pulsatile doses by another doctor. In the other two, dyskinesia was minimal. In contrast to this 4.9% cumulative incidence, dyskinesia occurred in 50% (17/34) of TT patients, an incidence similar to that in published data (p < 0.001).
Conclusion
Less pulsatile levodopa with 6 daily doses was associated with a low incidence of LID. Further study of this method of treatment is warranted.

Citations

Citations to this article as recorded by

Reduced Plasma Levodopa Fluctuations with More Frequent Administration of a Novel Carbidopa/Levodopa Functionally Scored Tablet
Thomas N. Chase, Ahmad AL‐Sabbagh, Minako Koga, Kathleen Clarence‐Smith
Clinical Pharmacology in Drug Development.2024; 13(4): 380. CrossRef
Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
Mechelle M. Lewis, Lauren J. Van Scoy, Sol De Jesus, Jonathan G. Hakun, Paul J. Eslinger, Julio Fernandez-Mendoza, Lan Kong, Yang Yang, Bethany L. Snyder, Natalia Loktionova, Sridhar Duvvuri, David L. Gray, Xuemei Huang, Richard B. Mailman
Biomolecules.2023; 13(5): 829. CrossRef
Classification of l-DOPA pharmacokinetics shapes and creating a predictive model
Noriko Nishikawa, Hirtotaka Iwaki, Yohei Mukai, Yuji Takahashi
Parkinsonism & Related Disorders.2023; 114: 105798. CrossRef
Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
Helga María Grétarsdóttir, Erik Widman, Anders Johansson, Dag Nyholm
Journal of Personalized Medicine.2021; 11(8): 720. CrossRef
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska
Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef
Pallidal versus subthalamic nucleus deep brain stimulation for levodopa‐induced dyskinesia
Shi‐Ying Fan, Kai‐Liang Wang, Wei Hu, Robert S. Eisinger, Alexander Han, Chun‐Lei Han, Qiao Wang, Shimabukuro Michitomo, Jian‐Guo Zhang, Feng Wang, Adolfo Ramirez‐Zamora, Fan‐Gang Meng
Annals of Clinical and Translational Neurology.2020; 7(1): 59. CrossRef
A Stage-Based Approach to Therapy in Parkinson’s Disease
Claudia Carrarini, Mirella Russo, Fedele Dono, Martina Di Pietro, Marianna G. Rispoli, Vincenzo Di Stefano, Laura Ferri, Filomena Barbone, Michela Vitale, Astrid Thomas, Stefano Luca Sensi, Marco Onofrj, Laura Bonanni
Biomolecules.2019; 9(8): 388. CrossRef
The Gut Microbiome: A Therapeutically Targetable Site of Peripheral Levodopa Metabolism
Eoin Mulroy, Kailash P. Bhatia
Movement Disorders Clinical Practice.2019; 6(7): 547. CrossRef

Individual Therapeutic Singing Program for Vocal Quality and Depression in Parkinson’s Disease: Eun Young Han, Ji Young Yun, Hyun Ju Chong, Kyoung-Gyu Choi; J Mov Disord. 2018;11(3):121-128. Published online August 9, 2018; DOI: https://doi.org/10.14802/jmd.17078

12,633 View
294 Download
14 Web of Science
10 Crossref

Abstract PDF Supplementary Material

Objective
Patients with Parkinson’s disease (PD) frequently experience depression associated with voice problems. Singing involves the use of similar muscles and the neural networks associated with vocal function and emotional response. The purpose of this study is to enhance vocal quality and depressive symptoms of patients with PD using individual singing program.
Methods
The Individual Therapeutic Singing Program for PD (ITSP-PD) was conducted by a certified music therapist. In total, nine PD patients with a subjective voice problem or depression participated in 6 sessions over 2 weeks. We measured the Maximum Phonation Time (MPT) via the Praat test, the Voice Handicap Index (VHI), the Voice-Related Quality of Life (V-RQOL) and the Geriatric Depression Scale (GDS).
Results
In total, 8 out of 9 patients completed all the sessions; 6 out of 8 patients participated in the follow-up test after 6 months. A statistically significant change in MPT (p = 0.011) was observed between the pre- and post-tests. The VHI (p = 0.035) and the GDS (p = 0.018) were significantly lower in the post-test. In the pre-, post-, and follow-up tests, the MPT (p = 0.030), V-RQOL (p = 0.008), and GDS (p = 0.009) were significantly changed.
Conclusion
The ITSP-PD based on neurological singing therapy for PD showed therapeutic possibility for vocal function and depression in patients with PD. Our findings suggest the need for a randomized study to examine the continuing positive effects of the ITSP-PD over a longer period of time.

Citations

Citations to this article as recorded by

Functional data analysis of prosodic prominence in Parkinson’s disease: a pilot study
Lauri Tavi, Nelly Penttilä
Clinical Linguistics & Phonetics.2024; 38(1): 64. CrossRef
Awareness of Dysphagia-Related Complications and Risks and the Importance of Early Intervention in Patients with Parkinson’s Disease: A Qualitative Study
Kaifeng Yao, Lihua Wang, Lihua Zhang, Aderito Seixas
International Journal of Clinical Practice.2023; 2023: 1. CrossRef
Group singing improves both physical and psychological wellbeing in people with and without chronic health conditions: A narrative review
Quinn Campbell, Sally Bodkin-Allen, Nicola Swain
Journal of Health Psychology.2022; 27(8): 1897. CrossRef
Defining the Therapeutic Singing Voice: Further Examination of the Everyday Singing Practices of Music Therapists
Martina C Bingham, Elizabeth K Schwartz, Anthony Meadows
Music Therapy Perspectives.2022; 40(1): 3. CrossRef
Music affects functional brain connectivity and is effective in the treatment of neurological disorders
Luisa Speranza, Salvatore Pulcrano, Carla Perrone-Capano, Umberto di Porzio, Floriana Volpicelli
Reviews in the Neurosciences.2022; 33(7): 789. CrossRef
Acute effects of singing on cardiovascular biomarkers
Kamila Somayaji, Mogen Frenkel, Luai Tabaza, Alexis Visotcky, Tanya Kruse Ruck, Ernest Kwesi Ofori, Michael E. Widlansky, Jacquelyn Kulinski
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Music Therapy and Parkinson’s Disease: A Systematic Review from 2015–2020
Manuel Joaquín Machado Sotomayor, Víctor Arufe-Giráldez, Gerardo Ruíz-Rico, Rubén Navarro-Patón
International Journal of Environmental Research and Public Health.2021; 18(21): 11618. CrossRef
The use of music as an arts-based method in migrant health research: a scoping review protocol
Fran Garry, Sylvia Murphy Tighe, Anne MacFarlane, Helen Phelan
HRB Open Research.2020; 3: 75. CrossRef
Walking the thin white line – managing voice in the older adult
Jacqui Allen, Anna Miles
Speech, Language and Hearing.2019; 22(1): 25. CrossRef
Music Therapy and Music-Based Interventions for Movement Disorders
Kerry Devlin, Jumana T. Alshaikh, Alexander Pantelyat
Current Neurology and Neuroscience Reports.2019;[Epub] CrossRef

Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders: Vibhash D. Sharma, Randi Jones, Stewart A. Factor; J Mov Disord. 2017;10(1):40-44. Published online December 27, 2016; DOI: https://doi.org/10.14802/jmd.16038

12,326 View
189 Download
12 Web of Science
12 Crossref

Abstract PDF

Objective
As the literature for the treatment of functional (psychogenic) movement disorders (FMD) is sparse, we assessed clinical outcomes in patients with FMD who underwent treatment with psychodynamic psychotherapy (PDP).
Methods
A retrospective analysis of the data of patients with FMD who were referred for PDP from 2008−2014 at Emory University Medical Center was performed.
Results
Thirty patients were included, mean age at presentation was 50 years (SD 13.9) and majority were female (27/30). Most common movement disorder was involuntary shaking/jerky movements (50%) and tremor (43%). Mean duration of symptoms was 3.2 years and mean number of PDP visits was 4.9. PDP lead to good outcomes in 10, modest in 8, and poor in 9. Three patients lost to follow up. Mean duration of symptoms between two groups (good vs. poor) was not statistically significant (p = 0.11), mean number of PDP visits showed a trend towards significance (p = 0.053). In all cases of good outcomes precipitants of the movement disorder were identified and a majority (60%) was receptive of the diagnosis and had good insight.
Conclusion
PDP lead to improvement in 60% of the patients which is encouraging as the treatment is challenging. This study supports heterogeneous causes of FMD including varied roles of past/recent events and demonstrates importance of psychological approaches such as PDP. Treatment with PDP should be considered in some patients with FMD but predicting who will respond remains a challenge. Further long term prospective studies with large sample size and placebo control are needed.

Citations

Citations to this article as recorded by

Functional Tic‐Like Behaviors: A Common Comorbidity in Patients with Tourette Syndrome
Kirsten R. Müller‐Vahl, Anna Pisarenko, Carolin Fremer, Martina Haas, Ewgeni Jakubovski, Natalia Szejko
Movement Disorders Clinical Practice.2024; 11(3): 227. CrossRef
Neuropsychiatric Treatment Approaches for Functional Neurological Disorder: A How to Guide
Sara A. Finkelstein, Caitlin Adams, Margaret Tuttle, Aneeta Saxena, David L. Perez
Seminars in Neurology.2022; 42(02): 204. CrossRef
Functional tremor
Petra Schwingenschuh, Alberto J. Espay
Journal of the Neurological Sciences.2022; 435: 120208. CrossRef
Psychological interventions for treating functional motor symptoms: A systematic scoping review of the literature
Erin M. Beal, Peter Coates, Cara Pelser
Clinical Psychology Review.2022; 94: 102146. CrossRef
Living with functional movement disorders: a tale of three battles. An interpretative phenomenological analysis
Sylwia Bazydlo, Fiona J. R. Eccles
Psychology & Health.2022; : 1. CrossRef
Management of Functional Seizures and Functional Movement Disorder: A Cross-Sectional Comparative Study
Bruno Gabriel Dal Pasquale, Hélio Afonso Ghizoni Teive, Marcelo Daudt von der Heyde, Luana Francine Anad Dal Pasquale
Neuropsychiatric Disease and Treatment.2022; Volume 18: 2121. CrossRef
Efficacy of a 5-day, intensive, multidisciplinary, outpatient physical and occupational therapy protocol in the treatment of functional movement disorders: A retrospective study
Megan Reid, Steven D. Mitchell, Katharine M. Mitchell, Christos Sidiropoulos
Journal of the Neurological Sciences.2022; 443: 120461. CrossRef
Diagnosis and therapy of functional tremor a systematic review illustrated by a case report
Michael Bartl, Rebekka Kewitsch, Mark Hallett, Martin Tegenthoff, Walter Paulus
Neurological Research and Practice.2020;[Epub] CrossRef
Speech, language and swallowing impairments in functional neurological disorder: a scoping review
Caroline Barnett, Jean Armes, Christina Smith
International Journal of Language & Communication Disorders.2019; 54(3): 309. CrossRef
Functional movement disorders in neurogeriatric inpatients
Sara Mätzold, Johanna Geritz, Kirsten E. Zeuner, Daniela Berg, Steffen Paschen, Johanne Hieke, Simone Sablowsky, Christian Ortlieb, Philipp Bergmann, Werner Hofmann, Alberto J. Espay, Walter Maetzler
Zeitschrift für Gerontologie und Geriatrie.2019; 52(4): 324. CrossRef
Psychogenic (Functional) Movement Disorders
Mary Ann Thenganatt, Joseph Jankovic
CONTINUUM: Lifelong Learning in Neurology.2019; 25(4): 1121. CrossRef
Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future
Karen S. Rommelfanger, Stewart A. Factor, Suzette LaRoche, Phyllis Rosen, Raymond Young, Mark H. Rapaport
Frontiers in Neurology.2017;[Epub] CrossRef

Review Articles

Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders: Wooseok Im, Jangsup Moon, Manho Kim; J Mov Disord. 2016;9(3):136-143. Published online September 21, 2016; DOI: https://doi.org/10.14802/jmd.16029

20,614 View
622 Download
14 Web of Science
10 Crossref

Abstract PDF

Gene therapy is a potential therapeutic strategy for treating hereditary movement disorders, including hereditary ataxia, dystonia, Huntington’s disease, and Parkinson’s disease. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome using modified nucleases. Recently, clustered regularly interspaced short palindromic repeat/CRISPR associated protein 9 (CRISPR/Cas9) has been used as an essential tool in biotechnology. Cas9 is an RNA-guided DNA endonuclease enzyme that was originally associated with the adaptive immune system of Streptococcus pyogenes and is now being utilized as a genome editing tool to induce double strand breaks in DNA. CRISPR/Cas9 has advantages in terms of clinical applicability over other genome editing technologies such as zinc-finger nucleases and transcription activator-like effector nucleases because of easy in vivo delivery. Here, we review and discuss the applicability of CRISPR/Cas9 to preclinical studies or gene therapy in hereditary movement disorders.

Citations

Citations to this article as recorded by

Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
Young Cha, Tae-Yoon Park, Pierre Leblanc, Kwang-Soo Kim
Journal of Movement Disorders.2023; 16(1): 22. CrossRef
Crispr-a novel approach towards a fortified immune system
Vasudevan Ranganathan, Padma Madham, Prerana Shankpal, Charitha Sheri
Journal of Microbiology & Experimentation.2023; 11(3): 73. CrossRef
Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases
Della Grace Thomas Parambi, Khalid Saad Alharbi, Rajesh Kumar, Seetha Harilal, Gaber El-Saber Batiha, Natália Cruz-Martins, Omnia Magdy, Arafa Musa, Dibya Sundar Panda, Bijo Mathew
Molecular Neurobiology.2022; 59(1): 191. CrossRef
Effects of the timing of electroporation during in vitro maturation on triple gene editing in porcine embryos using CRISPR/Cas9 system
Zhao Namula, Manita Wittayarat, Lanh Thi Kim Do, Thanh Van Nguyen, Qingyi Lin, Koki Takebayashi, Maki Hirata, Fuminori Tanihara, Takeshige Otoi
Veterinary and Animal Science.2022; 16: 100241. CrossRef
Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications
Precilla S. Daisy, Kuduvalli S. Shreyas, T. S. Anitha
Molecular Biotechnology.2021; 63(2): 93. CrossRef
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing
Parichehr Hassanzadeh
Life Sciences.2021; 274: 119289. CrossRef
CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models
Mahdi Barazesh, Shiva Mohammadi, Yadollah Bahrami, Pooneh Mokarram, Mohammad Hossein Morowvat, Massoud Saidijam, Morteza Karimipoor, Soudabeh Kavousipour, Amir Reza Vosoughi, Korosh Khanaki
Current Gene Therapy.2021; 21(2): 130. CrossRef
La edición del ADN
Ithzayana Madariaga-Perpiñan, Juan Camilo Duque-Restrepo, Paola Ayala-Ramirez, Reggie García-Robles
Iatreia.2020; 33(3): 262. CrossRef
Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective
Sachchida Nand Rai, Vivek K. Chaturvedi, Payal Singh, Brijesh Kumar Singh, M. P. Singh
3 Biotech.2020;[Epub] CrossRef
Current Approaches to the Treatment of Hunter Syndrome
Ekaterina Yu. Zakharova, Elena Yu. Voskoboeva, Alla N. Semyachkina, Nato D. Vashakmadze, Amina I. Gamzatova, Svetlana V. Mikhailova, Sergey I. Kutsev
Pediatric pharmacology.2018; 15(4): 324. CrossRef

Mechanism of Anti-α-Synuclein Immunotherapy: Jun Sung Lee, Seung-Jae Lee; J Mov Disord. 2016;9(1):14-19. Published online January 25, 2016; DOI: https://doi.org/10.14802/jmd.15059

25,514 View
332 Download
35 Web of Science
35 Crossref

Abstract PDF

Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.

Citations

Citations to this article as recorded by

Aggregation-Induced Emission Luminogens: A New Possibility for Efficient Visualization of RNA in Plants
Zheng-Chao Yang, Li-Xiang Zhao, Yu-Qi Sang, Xin Huang, Xuan-Chen Lin, Zhi-Ming Yu
Plants.2024; 13(5): 743. CrossRef
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
Acta Neuropathologica.2022; 143(1): 55. CrossRef
Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion
Shin Hye Noh, Ye Jin Kim, Min Goo Lee
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts
Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593. CrossRef
Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya
Immunology.2021; 162(2): 160. CrossRef
Electrogastrography for diagnosis of early-stage Parkinson's disease
Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina
Parkinsonism & Related Disorders.2021; 86: 61. CrossRef
Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf
Molecules.2021; 26(12): 3736. CrossRef
Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia
Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim
Neurochemical Research.2021; 46(12): 3123. CrossRef
Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh
CNS & Neurological Disorders - Drug Targets.2021; 20(9): 802. CrossRef
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
Pharmacological Reviews.2021; 73(4): 1204. CrossRef
Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson
Frontiers in Immunology.2020;[Epub] CrossRef
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
Translational Neurodegeneration.2020;[Epub] CrossRef
Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine
Frontiers in Neuroscience.2020;[Epub] CrossRef
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
Alzheimer's Research & Therapy.2020;[Epub] CrossRef
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
Molecular Neurobiology.2019; 56(7): 4799. CrossRef
The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies
Datis Kharrazian, Martha Herbert, Aristo Vojdani
Toxics.2019; 7(2): 26. CrossRef
Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model
Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman
Alzheimer's & Dementia.2019; 15(9): 1133. CrossRef
Translational therapies for multiple system atrophy: Bottlenecks and future directions
Nadia Stefanova
Autonomic Neuroscience.2018; 211: 7. CrossRef
Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway
Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang
Redox Biology.2018; 14: 600. CrossRef
Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood
Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus
Journal of Neuroimmunology.2018; 315: 33. CrossRef
Beneficial Effects of Flavonoids Against Parkinson's Disease
Un Ju Jung, Sang Ryong Kim
Journal of Medicinal Food.2018; 21(5): 421. CrossRef
Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
Jiyoon Kim, Heon Yung Gee, Min Goo Lee
Journal of Cell Science.2018;[Epub] CrossRef
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova
Frontiers in Neuroscience.2018;[Epub] CrossRef
Gene therapy for neurological disorders: progress and prospects
Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah
Nature Reviews Drug Discovery.2018; 17(9): 641. CrossRef
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
Edward Rockenstein, Gary Ostroff, Fusun Dikengil, Florentina Rus, Michael Mante, Jazmin Florio, Anthony Adame, Ivy Trinh, Changyoun Kim, Cassia Overk, Eliezer Masliah, Robert A. Rissman
The Journal of Neuroscience.2018; 38(4): 1000. CrossRef
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace,
Journal of Neural Transmission.2017; 124(6): 721. CrossRef
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
Xiaoli Si, Jiali Pu, Baorong Zhang
Journal of Movement Disorders.2017; 10(2): 69. CrossRef
Membrane Trafficking Illuminates a Path to Parkinson’s Disease
Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki
The Tohoku Journal of Experimental Medicine.2017; 242(1): 63. CrossRef
Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus
Scientific Reports.2017;[Epub] CrossRef
Impact of aging immune system on neurodegeneration and potential immunotherapies
Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao
Progress in Neurobiology.2017; 157: 2. CrossRef
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt
PLOS ONE.2017; 12(9): e0184731. CrossRef
Vaccination strategies in tauopathies and synucleinopathies
Anne K. Braczynski, Jörg B. Schulz, Jan‐Philipp Bach
Journal of Neurochemistry.2017; 143(5): 467. CrossRef
Missions of <italic>Journal of Movement Disorders</italic>
Yun Joong Kim
Journal of Movement Disorders.2016; 9(1): 1. CrossRef
How strong is the evidence that Parkinson's disease is a prion disorder?
Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
Current Opinion in Neurology.2016; 29(4): 459. CrossRef

Cell Therapy Strategies vs. Paracrine Effect in Huntington’s Disease: Wooseok Im, Manho Kim; J Mov Disord. 2014;7(1):1-6. Published online April 30, 2014; DOI: https://doi.org/10.14802/jmd.14001

14,020 View
88 Download
6 Web of Science
5 Crossref

Abstract PDF

Huntington’s disease (HD) is a genetic neurodegenerative disorder. The most common symptom of HD is abnormal involuntary writhing movements, called chorea. Antipsychotics and tetrabenazine are used to alleviate the signs and symptoms of HD. Stem cells have been investigated for use in neurodegenerative disorders to develop cell therapy strategies. Recent evidence indicates that the beneficial effects of stem cell therapies are actually mediated by secretory molecules, as well as cell replacement. Although stem cell studies show that cell transplantation provides cellular improvement around lesions in in vivo models, further work is required to elucidate some issues before the clinical application of stem cells. These issues include the precise mechanism of action, delivery method, toxicity and safety. With a focus on HD, this review summarizes cell therapy strategies and the paracrine effect of stem cells.

Citations

Citations to this article as recorded by

Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases
Dongkyu Kim, Gun-Sik Cho, Choongseong Han, Dong-Hyuk Park, Hee-Kyung Park, Dong-Hun Woo, Jong-Hoon Kim
Tissue Engineering and Regenerative Medicine.2017; 14(6): 653. CrossRef
Induced Pluripotent Stem Cells in Huntington’s Disease: Disease Modeling and the Potential for Cell-Based Therapy
Ling Liu, Jin-Sha Huang, Chao Han, Guo-Xin Zhang, Xiao-Yun Xu, Yan Shen, Jie Li, Hai-Yang Jiang, Zhi-Cheng Lin, Nian Xiong, Tao Wang
Molecular Neurobiology.2016; 53(10): 6698. CrossRef
Stem Cells in Neurological Disorders: Emerging Therapy with Stunning Hopes
Ghanshyam Upadhyay, Sharmila Shankar, Rakesh K. Srivastava
Molecular Neurobiology.2015; 52(1): 610. CrossRef
Genome Modification Leads to Phenotype Reversal in Human Myotonic Dystrophy Type 1 Induced Pluripotent Stem Cell-Derived Neural Stem Cells
Guangbin Xia, Yuanzheng Gao, Shouguang Jin, S.H. Subramony, Naohiro Terada, Laura P.W. Ranum, Maurice S. Swanson, Tetsuo Ashizawa
Stem Cells.2015; 33(6): 1829. CrossRef
Glycogen synthase kinase 3β inhibition enhanced proliferation, migration and functional re-endothelialization of endothelial progenitor cells in hypercholesterolemia microenvironment
Bin Cui, Jun Jin, Xiaohan Ding, Mengyang Deng, Shiyong Yu, MingBao Song, Yang Yu, Xiaohui Zhao, Jianfei Chen, Lan Huang
Experimental Biology and Medicine.2015; 240(12): 1752. CrossRef

First
Prev
Page of 1
Next
Last

Search